Goldman Sachs Group Inc. Increases Stock Holdings in Haleon PLC Sponsored ADR $HLN

Goldman Sachs Group Inc. raised its stake in Haleon PLC Sponsored ADR (NYSE:HLN) by 18.0% during the 4th quarter, HoldingsChannel.com reports. The firm owned 10,441,178 shares of the company’s stock after acquiring an additional 1,589,494 shares during the period. Goldman Sachs Group Inc.’s holdings in Haleon were worth $105,560,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in HLN. Norges Bank acquired a new stake in shares of Haleon in the fourth quarter valued at approximately $163,529,000. Bank of America Corp DE boosted its holdings in shares of Haleon by 116.7% in the second quarter. Bank of America Corp DE now owns 12,384,135 shares of the company’s stock valued at $128,423,000 after acquiring an additional 6,669,923 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Haleon by 36.6% in the third quarter. JPMorgan Chase & Co. now owns 11,984,672 shares of the company’s stock valued at $107,503,000 after acquiring an additional 3,207,986 shares during the period. Natixis Advisors LLC boosted its holdings in shares of Haleon by 429.8% in the fourth quarter. Natixis Advisors LLC now owns 10,003,941 shares of the company’s stock valued at $101,140,000 after acquiring an additional 8,115,633 shares during the period. Finally, Optiver Holding B.V. acquired a new stake in shares of Haleon in the third quarter valued at approximately $45,593,000. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

Haleon Price Performance

Haleon stock opened at $9.12 on Wednesday. Haleon PLC Sponsored ADR has a 12 month low of $8.65 and a 12 month high of $11.28. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.92 and a quick ratio of 0.71. The business has a 50 day simple moving average of $9.40 and a 200-day simple moving average of $9.92. The stock has a market capitalization of $40.37 billion, a PE ratio of 23.37, a price-to-earnings-growth ratio of 2.02 and a beta of 0.13.

Haleon (NYSE:HLN) last released its quarterly earnings results on Saturday, February 14th. The company reported $6.32 EPS for the quarter. The company had revenue of $3.65 billion for the quarter. Equities analysts predict that Haleon PLC Sponsored ADR will post 0.56 earnings per share for the current year.

Wall Street Analysts Forecast Growth

HLN has been the subject of several research analyst reports. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Haleon in a report on Thursday, April 30th. Wall Street Zen raised Haleon from a “hold” rating to a “buy” rating in a report on Saturday, March 21st. Finally, Argus raised Haleon to a “strong-buy” rating in a report on Tuesday, March 17th. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy”.

About Haleon

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.